Where it trades today
trading 47% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- CVS is valued near its sector range at 23.4x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- CVS carries a beta of 0.58, which means the stock should be judged on how it affects total portfolio swings, not just on standalone upside.
- CVS remains in a bearish short-term trend and sits 19.7% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- CVS is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in CVS.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for CVS come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for CVS. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What CVS Health Corporation does
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management…
What analysts expect
CVS carries a strong buy consensus from 25 analysts, with an average price target of $116.28 versus $88.84 today (+30.9%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
CVS generated $412.64B in trailing revenue (7.1% year over year), with a 1.2% net margin, and $8.08B of free cash flow, against $62.35B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $402.07B | $55.36B | $10.38B | $1.77B | $1.40 | $7.81B |
| 2024 | $372.81B | $51.40B | $9.70B | $4.61B | $3.67 | $6.33B |
| 2023 | $357.78B | $54.43B | $14.60B | $8.34B | $6.49 | $10.39B |
| 2022 | $322.47B | $54.50B | $16.29B | $4.31B | $3.29 | $13.45B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
CVS beside the healthcare names it is usually measured against.
What the chart is saying
CVS Health Corporation trades at $88.84, 19.7% below its 52-week high. With a beta of 0.58, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is CVS a good buy right now?
CVS Health Corporation trades at 23.4x earnings. This is near market average. Current risk level is Medium based on 21.9% volatility.
Does CVS pay dividends?
Yes, CVS Health Corporation offers a dividend yield of 2.95%. That is roughly $2.62 per share a year.
How volatile is CVS?
With 30-day annualized volatility of 21.9% and beta of 0.58, CVS is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for CVS?
The average analyst price target for CVS Health Corporation (CVS) is $116.28 based on 25 analyst estimates, about 30.9% above the current price of $88.84. The published range runs from $103.00 to $148.00.
How much revenue does CVS generate?
CVS Health Corporation reported $412.64B in trailing twelve-month revenue. Revenue growth is running at 7.1% year over year. Net margin sits at 1.2%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.